Innovations in Pharmaceutical Technology (IPT)
IPT provides a platform for cutting-edge ideas, concepts, and developments shaping the future of pharmaceutical R&D.
Install App?
Innovations in Pharmaceutical Technology (IPT)
www.iptonline.com
This is how the Install App dialog will look like once your App goes live.
11th July 2023 -- Staad, Switzerland -- Biosynth, a supplier of critical raw materials to the life science industry, is pleased to announce today that it has acquired celares, a leader in the development and manufacture of conjugate vaccines and bioconjugate drugs, activated PEGs and polymer based drug delivery excipients.
The acquisition will strengthen Biosynth’s exposure to the fast growing conjugate vaccines and bioconjugate drugs market. Expanding its capabilities and enabling Biosynth to offer the bioconjugation of antibodies, antigens and peptides to its existing pharma and diagnostics customer base; from GMP facilities located in Berlin, Germany.
Commenting, Dr Urs Spitz, CEO and president of Biosynth, said, “celares is an established leader in bioconjugation and we are extremely excited to be acquiring such a great team of specialists. celares is a perfect complement to our wider business, enabling us to provide bioconjugation services and the production of PEGylation reagents and polymers for drug delivery. Together, we can support customers from development to commercialisation. celares is a perfect fit for Biosynth - where chemistry meets biology.”
“We are thrilled to have joined the Biosynth group,” added Dr Ralf Kraehmer, managing director of celares. “As established leaders in bioconjugation, celares combines decades of chemical and biotechnological experience within the company and offers customers the possibility to access forward-looking technologies. Optimal polymer-based conjugations and formulations and manufacturing processes of drug compounds is part of our development. We see great similarities in Biosynth with their customer-led strategy and passion for the life science industry.”
About Biosynth
Biosynth is a supplier of critical materials, securing life science supply chains with global research, manufacturing and distribution facilities. Supplying the pharmaceutical and diagnostic sectors; where Chemistry meets Biology, Products meet Services and Innovation meets Quality, Biosynth is at the Edge of Innovation. With an unrivalled research product portfolio of over a million products and end-to-end manufacturing services, Biosynth’s expertise and capability runs across Complex Chemicals, Peptides and Key Biologics, all from one trusted partner. Headquartered in Staad, Switzerland, Biosynth is owned amongst others by KKR, Ampersand Capital Partners and management. Find out more about Biosynth at www.biosynth.com.
About celares
celares GmbH is focused on development and manufacturing of polymer-based drug delivery excipients and bioconjugate drugs. Established in 2003 and based in Berlin, Germany, celares is a leader in the field of bioconjugation/half-life extension by chemical modification and the synthesis of specialty polymers for drug delivery. celares provides high-quality customised services, including feasibility studies, up-scaling and process development, as well as the development and validation of required analytical methods. Furthermore, celares is offering GMP production of bioconjugates and functionalised polymers used as excipients in drug formulation. For more information, please visit www.celares.com.
![[object Object]](https://cdn.magloft.com/pwa-665/article/image/c8cfb798-e19d-4bbe-b36c-3e8cfe75ef4e.png?optimizer=image&width=360&aspect_ratio=3:4)
Broken String Biosciences Strengthens Senior Leadership Team to Accelerate Product Development
2 October 2023 -- Cambridge, UK -- Broken String Biosciences, a genomics company building a technology platform to drive the development of cell and gene therapies that are safer by design, announced the expansion of its senior leadership team with the appointments of Vincent Smith, PhD, as chief technology officer and Jessica Rich as VP Business Development
![[object Object]](https://cdn.magloft.com/pwa-665/article/image/b2fdfcd9-5174-45b6-8d1d-9b641ad7095a.png?optimizer=image&width=360&aspect_ratio=3:4)
Austrian State Secretary to speak at FlyPharma Europe 2023
29 September 2023 -- London, UK -- FlyPharma Europe will welcome Mr Florian Tursky, the Austrian state secretary, to the conference on 10 October, where he will deliver an opening speech. He will join a host of expert industry speakers from both pharma and cargo sectors
![[object Object]](https://cdn.magloft.com/pwa-665/article/image/e27828aa-7431-445b-8b52-d6d3b9228649.png?optimizer=image&width=360&aspect_ratio=3:4)
Revvity Expands Access to Base Editing Technology with Aim to Accelerate Discovery to Cure
26 September 2023 -- Massachusetts, US -- Revvity unveils its groundbreaking Pin-point base editing platform reagents, providing researchers with unparalleled access to implement the advanced gene editing technique in their preclinical laboratories
![[object Object]](https://cdn.magloft.com/pwa-665/article/image/589e2bd7-77cb-43d6-ac4a-f0180b72bb89.png?optimizer=image&width=360&aspect_ratio=3:4)
Cellectricon Expands Neuroscience Contract Research Portfolio with New Neuroplasticity Services
26 September 2023 -- Molndal, Sweden -- Cellectricon, a services provider dedicated to advancing neuroscience drug discovery, announced the launch of a new service module for neuroplasticity research
![[object Object]](https://cdn.magloft.com/pwa-665/article/image/3d896106-9683-4d84-b2bf-6db473ad2a53.png?optimizer=image&width=360&aspect_ratio=3:4)
Start Codon Invites Life Sciences Leaders, Founders and Investors to Innovation Showcase 2023
26 September 2023 -- Cambridge, UK -- Start Codon, a life science and healthcare venture-building fund, is pleased to invite life sciences leaders, entrepreneurs and investors from across the life science and biotech industries to attend their Innovation Showcase 2023
1
Human-Centred Design: From Inception to Integration
IPT sat down with Dr Chris Vincent at PDD, to understand more about the digital innovations that are leading design and whether technologies like Extended Reality (XR) can be beneficial to the process
2
The Importance of Temperature Control in Pharmaceutical Analysis
As technology within the analysis sphere continues to evolve, temperature control is becoming increasingly important for drug discovery and research
3
Providing Support Throughout the Patient Journey
Concierge services are critical to helping patients navigate technology and other logistics in a decentralised clinical trial. How best can they be implemented?
